TPTX News and Press, Turning Point Therapeutics Inc. From 03/01/21

The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Turning Point Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation

Turning Point Therapeutics (TPTX): Q4 GAAP EPS of -$1.02 misses by $0.09.Cash, Cash Equivalents, and Marketable Securities of $1.1 Billion Expected to Fund Current Operations into 2024.Press Release For further details see: Turning Point Therapeutics EPS misses by $0.09

Continued Strong Enrollment in TRIDENT-1 Registrational Study, with Phase 1/2 Enrollment in EXP-1 Expected to Reach 50 Patients in 2Q; Type B Meeting with FDA Planned in 2Q TPX-0131 Phase 1/2 Study Approved by Australian Ethics Committee; IND Submission Planned in Marc...

Should Investors Have These Top Health Care Stocks On Their Watchlist? Health care stocks are one of the biggest winners to come out of this pandemic. It is one of the best sectors to invest in right now. The health care industry is one of the most complex and largest sectors in...

Precision oncology company Turning Point Therapeutics (NASDAQ: TPTX) has gotten off to a hot start since going public in April of 2019. The clinical-stage biotech now sports a market cap approaching $6 billion, up from $1.3 billion at the time of launch. This is in part thanks to a ...

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and year ended Dec. 31, 2020 financial results following the clos...

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the G...

Turning Point Therapeutics (TPTX) announces updated interim findings from the ongoing TRIDENT-1 study of repotrectinib in patients with ROS1-positive TKI-naïve non-small cell lung cancer ((NSCLC)). In a total of 15 patients enrolled in Phase 2 portion, confirmed objective response r...

Phase 2 Confirmed Objective Response Rate is 93% (95% CI: 68-100); Pooled Phase 1/2 Confirmed Objective Response Rate is 91% (95% CI: 71-99) Approximately 40 Patients with ROS1-Positive TKI-Naive Non-Small Lung Cancer Now Enrolled in Phase 1/2 TRIDENT-1 Study ...

Present Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Jan. 31 at World Conference on Lung Cancer Provide TRIDENT-1 Study Timeline in First Quarter Provide Clinical Data Interim Updates from Multipl...